Severe pancytopenia after leflunomide in rheumatoid arthritis

Acta Medica Austriaca

Volumn 27, Issue 4, 2000, Pages 131-132

  Auer, J ^a   Hinterreiter, M ^a   Allinger, S ^a   Kirchgatterer, A ^a   Knoflach, P ^a  

^a GENERAL HOSPITAL   (Austria)

Author keywords

Bone marrow toxicity; Leflunomide; Pancytopenia; Rheumatoid arthritis

Indexed keywords

ACEMETACIN; ALENDRONIC ACID; ANTIRHEUMATIC AGENT; AUROTHIOMALATE; CALCITRIOL; CHLOROQUINE; CITRATE CALCIUM; LEFLUNOMIDE; METHOTREXATE; PIPERACILLIN; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAZOBACTAM; TOBRAMYCIN;

ADULT; ARTHRALGIA; ARTICLE; BONE MARROW TOXICITY; CASE REPORT; CLINICAL FEATURE; DRUG EFFECT; DRUG RESPONSE; FEMALE; FEVER; HUMAN; MALAISE; NAUSEA; OSTEOPOROSIS; PANCYTOPENIA; RHEUMATOID ARTHRITIS; STREPTOCOCCUS INFECTION; SYMPTOM; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; BONE MARROW; FEMALE; FILGRASTIM; HUMANS; ISOXAZOLES; MIDDLE AGED; PANCYTOPENIA;

EID: 0033695542     PISSN: 03038173     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1563-2571.2000.00034.x     Document Type: Article

References (4)

1. The immunosupressive metabolite of leflunomide, A77 1726, affects murine T-cells through two biochemical mechanisms
2. Mechanism of action of leflunomide in rheumatoid arthritis
3. Safety and effectiveness of leflunamide in the treatment of patients with active rheumatoid arthritis
4. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial